EPAS1 and breast carcinoma: Indeed, USP9X overexpression increased HIF-2α levels in a dose-dependent manner, without affecting the HIF-1α levels which has been reported as a USP9X substrate in breast cancer [35] (Fig. 4A and Supplementary Fig. S4A).